课题基金 / 基金详情

Imaging Inflammation in Asthma

Imaging Inflammation in Asthma
哮喘炎症的影像学检查
批准号:
7936227
负责人:
Serpil C. Erzurum
金额:
$16.93万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2012-08-31

项目摘要

项目成果

Serpil C. Erzurum的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):该申请涉及广泛的挑战领域(06):使能技术和特定挑战主题,06- hl -103:开发新的成像方法来跟踪细胞并准确测量完整细胞、组织和生物体中酶和代谢物的化学活性,以提高对细胞相互作用、生物途径及其调控的基本理解。在这个应用中,我们建议发展影像学方法来评估哮喘的气道炎症。哮喘是一种气道慢性炎症性疾病,涉及细胞和介质的相互作用,导致高水平的活性氧和活性氮(ROS, RNS)。细胞内谷胱甘肽的增加是对ROS/RNS的反应,是细胞对氧化环境耐受性的关键决定因素。我们和其他人已经表明,谷胱甘肽在哮喘气道中增加,并且随着哮喘的恶化,其水平急剧变化。在这里,我们假设使用放射性药物99mTc-HMPAO (technetium99m -六甲基丙烯胺肟)和单光子发射计算机断层扫描(SPECT)评估谷胱甘肽将识别和定位哮喘肺部的炎症区域。在GSH存在的情况下,亲脂性99mTc-HMPAO被定量地转化为亲水的非扩散形式,因此保留在组织内,导致SPECT上更高的摄取值。在目的1中,我们优化了SPECT-HMPAO扫描方法,并确定了哮喘小鼠模型中HMPAO摄取与GSH水平的关系。在目标2中,我们确定了哮喘患者和健康对照者99mTc- HMPAO摄取的差异,并确定了急性哮喘对过敏原反应后99mTc- HMPAO摄取的时间变化。在目标3中,我们量化了HMPAO摄取高与低的肺部区域的支气管镜样本中的炎症和谷胱甘肽水平,以验证SPECT-HMPAO图像与炎症部位相对应。总的来说,我们的目标是开发一种创新的、科学合理的、无创的方法来评估哮喘的局部炎症。炎症成像将是哮喘研究和哮喘患者临床护理的重要进展。
英文摘要
DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (06): Enabling Technologies and specific Challenge Topic, 06-HL-103: Develop new imaging methodologies to track cells and measure accurately the chemical activities of enzymes and metabolites in intact cells, tissues, and organisms to improve basic understanding of cellular interactions, biological pathways, and their regulation. In this application we propose to develop imaging methods to assess airway inflammation in asthma. Asthma is a chronic inflammatory disorder of the airways involving interaction of cells and mediators, which result in high levels of reactive oxygen and nitrogen species (ROS, RNS). Increase of intracellular glutathione is a response to ROS/RNS, and a critical determinant of cellular tolerance to oxidizing environments. We and others have shown that glutathione is increased in asthmatic airways and that levels change acutely with asthma exacerbations. Here, we hypothesize that assessment of glutathione using the radiopharmaceutical 99mTc-HMPAO (Technetium99m-hexamethylpropylene amine oxime) and single photon emission computed tomography (SPECT), will identify and localize regions of inflammation in asthmatic lungs. The lipophilic 99mTc-HMPAO is quantitatively converted to a hydrophilic nondiffusible form in the presence of GSH and thus retained within tissues leading to greater uptake values on SPECT. In aim 1, we optimize methods for SPECT-HMPAO scanning and determine the relationship of HMPAO uptake to GSH levels in a murine model of asthma. In aim 2, we identify differences in 99mTc- HMPAO uptake among asthmatics and healthy controls, and determine the temporal change(s) in 99mTc- HMPAO uptake following an acute asthmatic response to allergen. In aim 3, we quantitate inflammation and glutathione levels in bronchoscopic samples of lung regions that have high vs. low HMPAO uptake in order to validate that the SPECT-HMPAO image corresponds to sites of inflammation. Overall, our goal is to develop an innovative and scientifically sound noninvasive method for evaluation of regional inflammation in asthma. Inflammation imaging would be a significant advance highly relevant for asthma research and potentially the clinical care of asthmatic patients. PUBLIC HEALTH RELEVANCE: Asthma is a syndrome of airway inflammation that leads to obstruction of airflow to the lungs. Although defined as chronic inflammation of the airways, assessment of inflammation is not routine, and evaluation of regional airway inflammation is not currently possible except by invasive bronchoscopy. Our goal in this study is to develop a noninvasive imaging method based on chemical activities of metabolites in the lung for evaluation of regional inflammation in asthma. Specifically, total glutathione, a peptide that undergoes reversible reduction oxidation, is increased in asthmatic lungs due to the oxidative stress associated with chronic inflammation. We plan to assess lung glutathione using the radiopharmaceutical 99mTc-HMPAO (Technetium99m-hexamethylpropylene amine oxime) and single photon emission computed tomography (SPECT) imaging to identify and quantify regions of inflammation in asthma. The lipophilic 99mTc-HMPAO is quantitatively converted to a hydrophilic nondiffusible form in the presence of reduced glutathione and retained within tissues. We plan to evaluate HMPAO-SPECT imaging in murine models of asthma and human asthmatics. The discoveries from this study will reveal new knowledge of asthma pathogenesis and are likely to transform how we perform clinical-translational research studies in asthma in the future.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)
  • 批准号:
    9406651
  • 项目类别:
  • 资助金额:
    $35.03万
  • 财政年份:
    2017
  • 负责人:
    Serpil C. Erzurum
  • 依托单位:
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)
海外基金